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ABSTRACT
Background    Nephrogenic diabetes insipidus (NDI) is 
a rare disease whose complications include polyuria, re-
nal dysfunction, growth disorder and mental retardation. 
The details of NDI’s clinical course have been unclear. 
To address this uncertainty, we performed a large inves-
tigation of the clinical course of NDI in Japan.
Methods    Between December 2009 and March 2011, 
we provided a primary questionnaire to 26,282 members 
of the Japan Endocrine Society, the Japanese Urological 
Association, the Japanese Society for Pediatric Endocri-
nology, the Japanese Society for Pediatric Nephrology, 
the Japanese Society of Nephrology, the Japanese Soci-
ety of Neurology and the Japanese Society of Pediatric 
Urology. In addition, we provided a secondary question-
naire to 121 members who reported experience with 
cases of NDI. We asked about patient’s age at onset, di-
agnosis, complications, effect of treatment and patient’s 
genotype. 
Results    We enrolled 173 patients with NDI in our 
study. Of these NDI patients, 143 were congenital and 30 
were acquired. Of the 173, 73 patients (42%) experienced 
urologic complications. Among the 143 with congenital 
NDI, 20 patients (14%) had mental retardation. Patients 
with NDI mainly received thiazide diuretics, and some 
patients responded to treatment with desmopressin ac-
etate (DDAVP). Gene analyses were performed in 87 
patients (61%) with congenital NDI, revealing that 65 
patients had an arginine vasopressin receptor type 2 
(AVPR2) gene mutation and that 8 patients (9.2%) had 
an aquaporin 2 (AQP2) gene mutation. Patients with 
the AVPR2 mutation (D85N) generally showed a mild 
phenotype, and we found that DDAVP was generally an 
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effective treatment for NDI among these patients. 
Conclusion    We suggest that adequate diagnosis and 
treatment are the most important factors for improving 
prognoses. We further suggest that gene analysis should 
be performed for optimal treatment selection and the 
early detection of NDI among siblings.
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Nephrogenic diabetes insipidus (NDI) is a rare disease 
that is characterized by an inability to concentrate urine 
due to insensitivity of the collecting tubule to arginine 
vasopressin.1 NDI can be either congenital or acquired. 
Common cases of congenital NDI (CNDI) result from 
mutations in the arginine vasopressin receptor 2 (AVPR2) 
gene, which has X-linked recessive inheritance.1, 2 Some 
other congenital cases result from mutations in the aqua-
porin 2 (AQP2) gene, which can have autosomal reces-
sive or dominant inheritance.1, 2 Acquired NDI is com-
monly caused by drugs, such as lithium and demeclocy-
cline.3 However, the clinical status of NDI has remained 
unknown. 
 CNDI is commonly diagnosed as a result of charac-
teristic symptoms, such as polyuria, polydipsia, fever of 
unknown etiology, convulsion, vomiting and constipa-
tion in early infancy.4 However, it has been reported that 
some cases of CNDI exhibit far milder symptoms such 
as night enuresis, and that the diagnosis is only made 
later through gene analyses.5 Further, the long-term ef-
fects of treatment for NDI, the prognosis of NDI and 
the correlation between the phenotype and genotype in 
cases of NDI all remain unknown. 
 In Japan, Imura et al.6 carried out a nationwide 
survey for 5 “hormone receptor diseases” including 
NDI from 1977 to 1982. It was reported that there were 
78 cases of NDI, which seemed to be comprised of at 
least 2 subtypes; early onset type and late onset type.6 
Because the responsible genes of CNDI such as AVPR2 
and AQP2 genes had not been detected at that time, they 
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were unable to provide a molecular biological diagnosis 
of CNDI with a mild phenotype and in female carriers.
 Hence, to ascertain the characteristics of NDI in the 
general population, we conducted the nationwide survey 
of NDI in Japan. Here, we report the results of this sur-
vey, including clinical findings at onset, complications, 
the effects of treatment and genotypes in Japan. 
   
MATERIALS AND METHODS
The questionnaire and data analysis
Between December 2009 and March 2011, we provided 
a primary questionnaire to 26,282 members of the Japan 
Endocrine Society, the Japanese Urological Association, 
the Japanese Society for Pediatric Endocrinology, the 
Japanese Society for Pediatric Nephrology, the Japanese 
Society of Nephrology, the Japanese Society of Neurol-
ogy and the Japanese Society of Pediatric Urology. On 
the primary questionnaire, we asked about experiences 
in clinical practice and the number of patients who had 
NDI. In addition, we provided a secondary questionnaire 
to 121 members (96 hospitals) who reported experience 
with cases of NDI. We asked about patient’s age at onset, 
diagnosis, complications, effect of treatment, patient’s 
genotype and administration of angiotensin-converting 
enzyme inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) during the fetal period. Gene analyses 
were performed in individual facilities. We used the re-
sults of gene analyses. Attending physicians determined 
the type of NDI and the presence of secondary urologic 
complications, based on disease’s clinical manifestation 
and patient’s laboratory data. When the same case was 
reported by multiple members, we excluded each of the 
redundant reports based on the age and sex of the pa-
tient or the name of the healthcare facility. In the survey, 
we asked for information regarding patients of all ages, 
complications, genders and races. We carefully ana-
lyzed the results of the secondary questionnaire. At least 
2 researchers checked each report, and several team 
meetings were conducted to ensure the accuracy of our 
survey results. To assess the coverage rate of our survey, 
we compared the number of NDI patients aged less than 
20 years in our survey with the number of patients who 
were registered as having CNDI in the Medical Aid 
Program for Chronic Pediatric Diseases of Specified 
Categories in Japan, from fiscal 2009 to fiscal 2011. The 
study was approved by the Ethics Committee of Tottori 
University (approval number 1384).
 
Statistical analysis 
For our statistical analyses, we relied on the Mann-
Whitney U-test and Fisher’s exact test. Values of P less 
than 0.05 were defined as significant.
RESULTS  
We received 5,139 responses to our primary question-
naire from 26,282 members. Together, the primary 
questionnaires reported 210 NDI patients. We provided 
a secondary questionnaire to 121 members (96 hospitals) 
who had reported experience with cases of NDI. Re-
spondents to the secondary questionnaire reported 183 
patients with NDI. Ten patients were excluded because 
of insufficient information; we analyzed 173 patients. 
Of these, 143 patients had CNDI (124 males and 19 fe-
males) and 30 patients had acquired NDI (14 males and 
16 females). There was no duplicated case. Our study 
included 96 CNDI patients who were under 20 years as 
of 2009. In the database of the Medical Aid Program 
for Chronic Pediatric Diseases of Specified Categories 
in Japan, a yearly mean of 131 CNDI patients were re-
Fig. 1. Histogram of the age at diagnosis with CNDI (a) and ac-
quired NDI (b). The number of male patients is depicted with a 
closed bar. The number of female patients is depicted with an open 
bar. CNDI, congenital NDI; NDI, nephrogenic diabetes insipidus.
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Table 1. Symptoms and signs at the onset of congeni-
tal NDI (n = 143)
Symptoms and signs n
Polyuria 79
Polydipsia 69
Thirst 19
Nocturnal enuresis 15
Fever 53
Poor weight gain 41
Failure to thrive 14
Mental retardation 8
Vomiting 12
Anorexia 6
Convulsion 3
Disturbance of consciousness 1
Constipation 1
Others* 9
 NDI, nephrogenic diabetes insipidus.
* Urinary tract infection, dysphoria, weight loss, bradycardia. 
ported from fiscal 2009 to fiscal 2011. Accordingly, the 
coverage achievement rate of our survey was estimated 
to be 73%, which is high.
Congenital NDI 
In this study, 143 patients had CNDI (124 males and 19 
females), out of a total of 173 patients with any form of 
NDI. Details of age at diagnosis are presented in Fig. 1. 
The median age of CNDI diagnosis was 2.0 months (n = 
125), and the mean [s] age was 1.2 [4.6] years (n = 125). 
Ninety-eight patients (69%) with CNDI were diagnosed 
within the 1st year of life, and 19 patients (13%) were 
diagnosed between 1 year and 4 years of age. Eight 
patients with CNDI were diagnosed between 5 and 29 
years of age, half of whom had siblings or children who 
were diagnosed with NDI beforehand. We were unable 
to obtain the information on the age of CNDI diagnosis 
in 18 patients. Three patients were diagnosed as with 
CNDI in their 20s, 1 of whom had the mutation p.D85N 
in the AVPR2 gene, which resulted in a mild phenotype, 
as was described subsequently.7
 The symptoms and signs at the onset of CNDI 
are presented in Table 1. Polyuria was the most com-
mon symptom at onset (79 of the 143 patients; 55%). 
Polydipsia was the second common symptom (69 of 
the 143; 48%). It is well known that many patients with 
CNDI have fever at onset;5 53 patients (37%) had fever 
at onset and 30 patients with CNDI (21%) presented no 
symptoms at onset except for fever. Although it has been 
reported that vomiting and anorexia occur at the onset 
of 70% of CNDI patients,5 vomiting and anorexia were 
found in only 18 patients (13%) in our study. On the 
other hand, infant patients (diagnosed before 6 months 
of age, n = 90) were more likely to present with fever at 
onset (49 of the 90; 54%) than the total survey sample. 
Approximately 40% of the patients who were less than 
6 months had either poor weight gain, or polydipsia and 
polyuria. Eight patients (5.6%) with CNDI were diag-
nosed among those who already had mental retardation 
(MR).
 The incidence of MR is critically related to progno-
sis such as quality of life. Twenty patients with CNDI 
(14%) were complicated with MR. In 3 of the 20, MR 
was severe. Because of the limited sample size, we could 
not find any significant differences in age (P = 0.908, 
Mann-Whitney U-test) or the serum sodium levels in 
CNDI patients with and without MR at the time of diag-
nosis. However, patients with MR were diagnosed at an 
age range from 0.5 to 2.5 years, and generally appeared 
to be older than patients with other complications at the 
time of diagnosis (the mean age of CNDI diagnosis was 
2.0 months overall). 
 
Genetic analysis
Analyses of the AVPR2 and/or AQP2 genes were per-
formed for 87 (61%) of all CNDI patients. For 10 of the 
87, we were unable to obtain the name of the gene in 
which a mutation was detected. Most of them (65 of 87; 
75%) had AVPR2 gene mutations, surprisingly includ-
ing 10 female patients. On the other hand, AQP2 gene 
abnormalities were identified in 8 patients (4 males and 
4 females; 9.2%). In 4 patients (2 males and 2 females; 
4.6%), AVPR2 or AQP2 mutation was not detected by 
mutation analysis. Our survey results included 35 dis-
tinct AVPR2 mutations and 4 distinct AQP2 mutations 
that caused CNDI (Tables 2 and 3). Of the 39 mutations, 
14 (12 in AVPR2 and 2 in AQP2) have not been reported 
previously. These novel AVPR2 and AQP2 mutations 
are marked in Tables 2 and 3. Missense mutations in 
the AVPR2 gene were the most common mutations. The 
p.D85N mutation was detected in 7 patients (11%) of the 
65, and p.R106C was detected in 5 (7.7%). In previous 
reports, p.D85N, p.V88M, p.R104C, p.R106C, p.Y128S, 
p.N317K, p.P322S, p.S333del AVPR2 gene mutations 
were reported as being associated with a mild pheno-
type;7, 8 these were detected in 22 patients (34%) of the 
65 in our study. Of the 22, 19 patients (81%) were diag-
nosed at the age younger than 3 years, and 11 patients 
(50%), at the age younger than 6 months. Ten patients 
were diagnosed after 3 years of age; p.D85N, p.R104C, 
and p.Y128S were among the mutations detected in 
these patients, as was W99X (1 case), a previously unre-
ported mutation. Four of the 10 patients did not receive 
gene analyses.
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Table 4. Urologic complications in patients with NDI 
(n = 173)
Symptoms and signs n
Hydronephrosis 47
Hydroureter 24
Renal failure 11
Vesicoureteral reflux 11
Slightly dilatation of renal pelvic  7
Dilatation of bladder 3
Renal atrophy/dwarf kidney 3
Neurogenic bladder 2
Acidosis 1
NDI, nephrogenic diabetes insipidus. 
Acquired NDI
The age of onset of acquired NDI ranged widely among 
patients. The peak age of onset was at approximately 
50 to 69 years. In 15 patients (50%), acquired NDI was 
caused by administration of lithium carbonate. Between 
10 and 49 years of age, the ratio of female patients with 
acquired NDI was higher. This sex difference may be 
due to the fact that both depression and bipolar disorder, 
which are treated with lithium carbonate, are more com-
mon in females. Two patients acquired NDI by ACEI or 
ARB treatments for their mothers during the fetal pe-
riod. In 13 patients, the underlying cause was unknown. 
Seven patients with acquired NDI (23%) had MR as a 
complication. MR was severe in 3 of them.
Urologic complications of NDI
In 73 patients (42%) of the 173, NDI was accompanied 
by urologic complications. The frequencies of various 
urologic complications are presented in Table 4. Eleven 
patients (6.4%) had renal failure. We found no significant 
difference in the rate of whole urologic complication 
between CNDI and acquired NDI (P = 0.536, Fisher’s 
exact test). However, CNDI was more frequently accom-
panied by hydronephrosis and/or hydroureter (P = 0.0454, 
Fisher’s exact test). Two cases lacked information on 
urologic complications. No patients required clean inter-
mittent catheterizations.
Treatment
Details of treatment efficacy are presented in Fig. 2. 
Most patients with NDI were treated with thiazide di-
uretics (hydrochlorothiazide or trichlormethiazide) with 
or without potassium supplementation, low-sodium diet, 
non-steroidal anti-inflammatory agents (NSAIDs) and 
aldosterone antagonists (amiloride or spironolactone).
 Thiazide diuretics were effective in 110 (92%) of 
120 patients with CNDI. All 15 patients treated with 
aldosterone antagonists were also treated with thiazide 
Table 2. Summary of AVPR2 mutations reported in this 
study
 Gene Type Mutation Frequency
 AVPR2 Complete 
    deletion 
– 2
 Splicing Intron 2† 1
 Missense A37P§ 1
  L44F 1
  D85N 7
  V88M 1
  R104C 2
  R106C 5
  G107E 1
  G107R§ 1
  R113W 1
  Y128S 2
  W164R 1
  P178L§ 1
  R181C 2
  R202C 3
  P286S 1
  N317K 1
  P322S 2
  S329G 1
  L336P§ 1
 Nonsense W99X§ 2
  W156X§ 1
  L161X 1
  W200X 1
  R337X 1
 Deletion c.528delG§ 1
  V278del§ 1
  S333del 1
  c.727-728delAG 1
  5’UTR-AVPR2 DEL 32,787 2
  Others 3
 Insertion c.299 300insA§ 1
  c.498 499insTC (L168RfsX45)§ 1
  c.855 856insCGCA§ 1
 Frameshift L35fs.§ 1
 Unknown‡ − 8
  AVPR2, arginine vasopressin receptor type 2.
† Splice acceptor AG  CG.
‡ There was a mutation but detail was unknown. 
§ Novel mutation. 
Table 3. Summary of AQP2 mutations reported in this 
study
Gene Type Mutation Frequency
AQP2 Missense A130V§ 1
  N184H§ 1
  R254Q 2
 Deletion c.763 722del 2
 Unknown‡ − 2
 AQP2, aquaporin 2.
‡ There was mutation but detail was unknown. 
§ Novel mutation. 
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diuretics. A low-sodium diet was useful for 32 (65%) of 
49 patients with CNDI. Desmopressin acetate (DDAVP) 
was provided in 32 patients (28 males and 4 females), 
which was effective in 8 patients [6 males (21%) and 2 
females (50%)] of them. The dose of DDAVP was not in-
vestigated in the questionnaire. All 8 patients who were 
effectively treated with DDAVP had AVPR2 gene muta-
tions (p.A37P, p.D85N, p.R104C, and p.Y128S) or AQP2 
gene mutations (p.R254Q and c.763_722del).
DISCUSSION
To our knowledge, we have conducted the nationwide 
survey of NDI in Japan, which has allowed us to evalu-
ate the characteristics of NDI—especially CNDI—in 
Fig. 2. The efficacy of therapy for CNDI (a) and acquired NDI 
(b). The patients in whom the treatment reduced urine volume are 
depicted with an open bar, and patients in whom treatment did not 
reduce urine volume are depicted with a closed bar. CNDI, con-
genital NDI; DDAVP, desmopressin acetate; NDI, nephrogenic 
diabetes insipidus; NSAID, non-steroidal anti-inflammatory agent. 
Japan. Our survey is believed to include almost 3/4 of 
CNDI patients in the Medical Aid Program for Chronic 
Pediatric Diseases of Specified Categories in Japan dur-
ing fiscal 2009.
 NDI is characterized by resistance of the kidney to 
AVP due to genetic or acquired causes.9 CNDI is rare, 
and is known to be caused by mutations in AVPR2 (Xq28) 
or AQP2 (12q13.12).1, 2, 3 In contrast, acquired NDI is 
generally an adverse effect to drugs including lithium, 
demeclocycline, and amphotericin. As can be expected 
from their different etiologies, most patients with CNDI 
are diagnosed in infancy,5, 10 and most of acquired NDI 
are diagnosed in adulthood. In our extensive study, we 
also found that 7.0% of patients with CNDI were diag-
nosed after the age of 3 years, including 3 patients who 
were diagnosed in their 20s. In general, patients with 
CNDI show polyuria and polydipsia from birth, as well 
as fever, poor weight gain and vomiting within the 1st 
week of life.11, 12 However, polyuria and polydipsia are 
not always the chief complaints associated with CNDI,5, 
10 and other various symptoms are usually found during 
infancy, such as fever, poor weight gain, failure to thrive, 
vomiting and anorexia. Furthermore, the results of our 
survey have revealed that 21% of CNDI patients present 
no symptoms except for fever at the time of onset. Our 
findings suggest that many clinicians already consider 
CNDI when facing a fever of unknown etiology in an 
infant, but that all clinicians should do so.
 As of October 2012, more than 220 mutations in the 
AVPR2 gene and more than 50 mutations in the AQP2 
gene have been identified as causing NDI.2, 7, 9, 13 Spana-
kis et al.7 found 13 hotspot mutations in the AVPR2 gene. 
These mutations were reported in more than 6 families 
with NDI.7 To evaluate whether there are clustered 
mutations among patients with CNDI in Japan, we con-
ducted a survey concerning the detection of mutations in 
the AVPR2 and AQP2 genes. Although some mutations 
were especially common (AVPR2 gene: p.D85N, 11% of 
patients with the gene; p.R106C, 7.7% of patients with 
the gene), we could not find clearly clustered mutations. 
However, analyses of mutations in AVPR2 and AQP2 
were not performed in 1/3 of the CNDI patients in our 
study. If all CNDI patients had received gene analyses, 
it is possible that p.D85N and p.R106C would have ap-
peared as more common mutations in the AVPR2 gene. 
Moreover, it has been reported that 14 mutations in the 
AVPR2 gene (p.D85N, p.V88M, p.R104C, p.R106C, 
p.Y128S, p.G201D, p.F287L, p.M311V, p.N317K, 
p.N317S, p.N321Y, p.P322S, p.S329R, p.S333del) are 
associated with partial CNDI, in which mild dysfunc-
tion of AVPR2 is exhibited in vitro.8 In our survey, these 
were detected in 22 (34%) of the 65 patients. Eleven (50%) 
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of the 22 were early diagnosed at age less than 6 months. 
Because of the small sample size, we could not analyze 
the relationship between age of diagnosis and genotype. 
However, AVPR2 gene mutations (p.A37P, p.D85N, 
p.R104C, and p.Y128S) or AQP2 gene mutations 
(p.R254Q and c.763_722del) were present in each of the 
8 patients with CNDI who were effectively treated with 
DDAVP. These AVPR2 gene mutations have previously 
been reported as being associated with a mild phonotype 
of CNDI.7, 8 It has been reported that the majority of the 
subjects with AQP2 gene mutations did not respond to 
DDAVP. Surprisingly, 4 (50%) of 8 patients with AQP2 
gene mutation had response to DDAVP.14 Accordingly, 
we suggest that gene analysis can play important roles in 
treatment selection and early detection of CNDI in sib-
lings.
 Commonly, female patients who have CNDI with 
the AVPR2 mutation are asymptomatic because the mu-
tation is heterozygous. However, our survey surprisingly 
included 10 female patients with CNDI and the AVPR2 
mutations (10 of 86 cases; 12%). Some studies have 
found that female carriers show a clinical phenotype 
similar to that of male carriers because of skewed X-
inactivation or Turner syndrome.15–17 Because our form 
questionnaires did not include details of genotype or X-
inactivation, we could not compare clinical form with 
genotype. However, our survey might reveal that there 
are more female cases with the AVPR2 mutation than 
has previously been expected. Further investigation is 
needed to clarify this issue.
 The optimal goals of treatments for NDI are to 
reduce urine volume and adequately replace lost wa-
ter through increased water intake. These goals are 
achieved to some extent by using low-sodium diets, 
thiazide diuretics, potassium-sparing diuretics (such as 
amiloride and aldosterone antagonists) and NSAIDs 
(such as indomethacin and selective cyclooxygenase-2 
inhibitors).11, 18–20 In some reports,18–21 urine volume 
decreased by 30% to 70% among patients who received 
diuretic therapy. If sufficient control of urine volume is 
not achieved through a single treatment, different treat-
ments are often combined. Although treatment of NDI 
with DDAVP is generally considered to be ineffective, it 
has been reported that high doses of DDAVP (10–40 μg) 
are effective for p.D85N, p.V88M, or p.R104C AVPR2 
gene mutations,5, 11, 21 which have mild phenotypes7, 8 as 
a consequence of the retained function of the AVPR2 re-
ceptor. In our study, DDAVP was effective in 4 patients 
with AVPR2 mutations that caused mild phenotypes 
(p.A37P, p.D85N, p.R104C, and p.Y128S), and in 4 pa-
tients with AQP2 mutations (p. R254Q, c.763_722del). 
Accordingly, if one of the above mutations is detected, 
treatment with DDAVP should be considered.
 MR is considered as a major complication of NDI, 
and is critically related to prognosis. In the original 
studies of NDI, it was reported that MR was prevalent 
in 70% to 90% of the patients.3 On the other hand, a 
report demonstrated that the majority of patients with 
NDI have normal intelligence.5, 22 In the present study, 
we found that 14% of CNDI patients are accompanied 
by MR. The results suggest that the actual prevalence 
of this complication is located between the findings of 
these 2 studies,3, 5 and MR may be avoided through 
treatment. Indeed, it has been reported that NDI leads to 
recurrent severe hyperosmotic dehydration1, 11 and brain 
edema brought about by attempts to rehydrate too quick-
ly.11 These events damage both endothelial and other 
brain cells, and deposit calcium phosphate and other 
substances, particularly within or around the wall of 
small vessels23, resulting in MR. In our study, 8 patients 
(5%) already had MR at the time of CNDI diagnosis. 
Moreover, patients with CNDI and MR at onset tend to 
be diagnosed at an age that is older than the mean age of 
CNDI diagnosis. These findings indicate that the early 
diagnosis and careful treatment play an important role in 
preventing MR.
 Megacystis, trabeculated bladder wall, hydroureter, 
hydronephrosis and other urinary tract abnormalities are 
major complications of NDI that result from persistent 
polyuria.12 Although Uribarri et al. reported that urinary 
tract abnormalities were found in 67% of patients with 
NDI in the United States,24 such abnormalities were 
found in only 73 patients (42%) in our study. Eleven 
patients (6.4%) experience renal failure in our study. 
Because ultrasonic examination is widely recognized as 
important tool for the early detection of urologic com-
plications, we suggest that ultrasonographic follow-up 
should be performed for all NDI patients. Further, ade-
quate treatment and control of NDI should be performed 
to prevent the complication of urinary tract abnormali-
ties. Additionally, adequate treatment of urinary tract 
abnormalities is also needed to prevent acquired NDI.
 It is widely recognized that several drugs can cause 
acquired NDI, including lithium, demeclocycline and 
amphotericin. Of the drugs that are capable of inducing 
NDI, lithium is prescribed most frequently.18 It is report-
ed that over 40% of patients treated with lithium develop 
NDI as an adverse effect.25 In our study, 15 patients (50%) 
with lithium-induced NDI were detected. Our sample 
size was too limited to investigate the actual conditions 
of acquired NDI because we were unable to provide this 
survey to members of the Japanese Society of Psychiatry 
and Neurology. However, our findings suggest that all 
patients receiving lithium treatment should be checked 
for acquired NDI. 
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 In conclusion, we have presented the results of the 
nationwide survey of NDI in Japan. Our findings suggest 
the existence of a form of CNDI with mild symptoms, 
which is often diagnosed at older ages. We suggest that 
adequate diagnosis and treatment are the most important 
factors for improving prognoses. We further suggest that 
gene analysis should be performed for optimal treatment 
selection and the early detection of NDI among siblings.
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